Bronchodilator use in asthma: the art of prescribing bronchodilators correctly, taking advantage of their differences and reducing risks by Fernandes, Ana Luisa Godoy
J Bras Pneumol. 2006;32(3):xi-xii
Editorial
The history of the development of bronchodilators
of the β2-agonist  group, which evolved
concomitantly with the understanding of the
physiopathology of asthma, is an excellent
example of how scientific thinking develops,
based on hypotheses that comprise partial truths
and are progressively filtered in order to improve
the understanding of something that should
occur, but sometimes does not. Failures are
discovered from these continuous observations,
and we evolve toward a new generation of
intervention, in an attempt to determine the ideal
treatment. Formoterol, a long-acting β2-agonist
(LA β2), is analyzed in this issue of the Brazilian
Journal of Pulmonology regarding its efficacy in
reversing methacholine-induced bronchospasm.
The study compared formoterol with a short-acting
β2-agonist (SA β2), fenoterol, demonstrating the
equivalence of action of formoterol with one of
the drugs considered the gold standard for
reversibility of severe bronchospasm, the short-
acting bronchodilators. The study population was
selected from patients who sought diagnostic
clarification of their respiratory symptoms at the
pulmonary function laboratory. The patients who
tested positive on the provocation test were
included in the study.(1)
The study protocol allows us to clearly observe
that the initial speed of action of the LA β2 is
equivalent to that of the SA β2, demonstrating a
truth that has come to stay: formoterol, in
addition to being devised as long-acting, also
has the property we seek, which is to promptly
relieve severe bronchospasm, and presents a great
advantage over salmeterol. This allows us to
advocate its use in severe bronchospasm.
This study leads to another quite relevant issue
that has been debated in the literature and was
the object of a perspectives article in the December,
2005 issue of the New England Journal of Medicine,
written by Prof. Dr. Fernando D. Martinez (invited
to participate in the next Brazilian Congress of
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SBPT - Fortaleza, 2006).(2) In that article, the use of
long-acting bronchodilators is discussed, together
with the review on the principal clinical studies that
led the FDA to include an alert, in the directions for
use, to the users of salmeterol, in July of 2005,
announcing a small, albeit significant, increase in
adverse events associated with asthma, and
characterized as imminent risk or complications or
death, present in a safety study recently completed in
the USA. Prof. Martinez questions the consequences
of this alert for the treatment of asthma.
This study, the Salmeterol Multi-center Asthma
Research Trial (SMART), initiated by GSK in July of
1996, was a 28-week safety study comparing
salmeterol to placebo in the treatment of asthma, in
addition to routine maintenance treatment. The
primary outcome was to observe the deaths and
serious adverse events related to asthma that
endangered the life of the patients (intubation and
mechanical ventilation). The study had the intention
of including 60,000 patients but was interrupted
by the sponsor after the interim analysis, which was
carried out with the inclusion of approximately
26,000 patients. They demonstrated a 4.4-times
higher relative risk of death in the salmeterol group
in relation to the placebo group. Another randomized
study, carried out in the United Kingdom and
published in 1993, comparing the use of salmeterol
with that of salbutamol and involving 25,000
patients, revealed that there fewer dropouts among
the patients who received salmeterol than among
those who received salbutamol (2.91% versus 3.79%;
χ2 = 13.6, p = 0.0002). Mortality was a little higher,
although not significantly so, in the salmeterol
group. The use of more than two units of rescue
bronchodilator (in addition to the maintenance dose)
presented significant association with the occurrence
of serious adverse events related to asthma.(3)
Unfortunately, none of the two studies was planned
to test the hypothesis of salmeterol being safe when
accompanied by the use of inhaled corticosteroid,
although LA B2s have been used as adjuvant therapy
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to inhaled cort icosteroid. The patients were
randomized with no control of the use and dose of
the inhaled corticosteroid during the clinical trial.
Therefore, this issue has yet to be clarified.
Reviewing the comments of Prof. Martinez, we are
brought back to very interesting occurrences of the
end of the last century. In the beginning of the 1990s,
a study by Sears et al.(4) provoked a great debate in
the literature when, through a randomized clinical trial,
it was demonstrated that the regular use of an SA ß2
four times a day was worse for the asthma patients
than the use of an SA ß2 when necessary, in relation
to the control of the disease. Therefore, they
questioned whether the regular use of this drug could
be the cause of uncontrolled asthma.(4) A retrospective,
epidemiological, population-based, nested case-
control study(5) involving 12,301 asthma patients
residing in Saskatchewan, Canada, demonstrated that
the risk of death by asthma was not related to the
regular use or even increased use of an SA β2 but to
the lack of use of the inhaled corticosteroid as
maintenance treatment. In addition, either because the
disease was uncontrolled or because it was untreated,
there was excessive use of the SA β2.
Therefore, when studies demonstrating the
superiority of the combination of an LA β2 in relation
to the increased dose of the inhaled corticosteroid
(in order to obtain the control of asthma) began to
appear,(6) this concept appeared to be in conflict. The
FACET study,(7) which compared the addition of an LA
β2, in low (200 mcg) or high (800 mcg) doses, to a
placebo, suggested that the high doses of inhaled
corticosteroid were associated with less frequent
exacerbations, and that the use of an LA β2 was
associated with more symptom-free episodes. Other
clinical trials followed, proving the efficacy of
combining an inhaled corticosteroid with an LA β2 in
controlling of asthma,(8) as well as discussing strategies
to improve this control.(9)
However, what worries us is the fact that some patients
do not manage to achieve good control of their asthma.
Do they constitute a special group of corticosteroid-
resistant patients? Are they responsive to other anti-
inflammatories? Do they present low compliance with
maintenance treatment? Or is there any other condition
that causes their inadequate response to ß-agonists? The
fact is that, for patients with more severe asthma, when
it is not possible to control the symptoms, it remains
doubtful as to whether they present an increased risk of
complications or even of fatal episodes when using the
maintenance therapy. One thing is certain: inhaled
corticosteroids are indisputably the best maintenance
treatment for asthma, and, when the effectiveness of a
β2-agonist in reversing severe bronchospasm is presented
in this issue of the Brazilian Journal of Pulmonology, it
is indispensable to reflect upon the advantages and risks
related to the use of bronchodilators, and remember
that they must always be combined with the anti-
inflammatory treatment of asthma.
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